Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia.
9 affiliations
- 1Medicines Intelligence Centre of Research Excellence, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
- 2Department of Medicine, Monash University, Clayton, Victoria, Australia.
- 3Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- 4Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- 5Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, New South Wales, Australia.
- 6Department of Rheumatology, Austin Health, Heidelberg, Victoria, Australia.
- 7Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia.
- 8Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
- 9Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Abstract
Aim
To describe Australian trends in JAKi uptake, where there are no restrictions on the sequence of their use in clinical practice.Methods
We included all people aged 18 years and over initiating a JAKi between 1 October 2015 and 31 August 2022. We used national dispensing claims data for a random 10% sample of Australians to: describe the number of people initiating JAKi per quarter; the characteristics of new JAKi users including demographics, use of other medicines to manage cardiovascular comorbid disease; and use of prior targeted therapy (biologics or small molecule inhibitors). We used Kaplan-Meier analysis to estimate the proportion of initiators who were persistent on their initial JAKi to 365 days.Results
We identified 2904 people initiating JAKi treatment between 1 October 2015 and 31 August 2022; new use increased consistently during the study period. 45% of initiators had not been dispensed a prior subsidised targeted therapy in 365 days prior to JAKi initiation; 72% of new users were female and 62% were aged 55 years or older. Almost half of people initiating JAKi had at least one marker of higher cardiovascular risk, with 30% dispensed medicines to treat or prevent cardiovascular disease in the year prior to initiation; and 34% being aged 65 years or older. 60% of people persisted on their initial JAKi therapy to 365 days. Of those who stopped, 51% switched to a biologic and 15% switched to a different JAKi.Conclusion
In a setting where JAKi are permitted to be used in any line of therapy, 45% of new users of JAKi were naïve to targeted therapy and half had at least one marker of cardiovascular risk. Continued monitoring is required to understand the risk profile of JAKi, particularly in those with high baseline cardiovascular disease risk.
Related
- Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population‐based cohort study
- Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance
- IL-17 Inhibitor-Associated New Onset Inflammatory Bowel Disease: Clinical Presentation and Management: A Report of Two Cases
- Health, diet and exercise needs of people living with bipolar disorder in Australia
- Measuring people’s experiences to inform integrated solutions to food and water security in Australia and the Asia Pacific region
BibTeX
@article{deakin2026janus,
title = {{Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia.}},
author = {Claire T Deakin and Michael O Falster and Geoffrey O Littlejohn and Peter Youssef and David Liew and Nicole L Pratt and Sallie-Anne Pearson},
journal = {Pharmacoepidemiology and drug safety},
year = {2026},
month = oct,
doi = {10.1002/pds.70503},
url = {https://europepmc.org/article/MED/42963129},
note = {CC BY},
}
RIS
TY - JOUR
TI - Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia.
AU - Claire T Deakin
AU - Michael O Falster
AU - Geoffrey O Littlejohn
AU - Peter Youssef
AU - David Liew
AU - Nicole L Pratt
AU - Sallie-Anne Pearson
PY - 2026
DA - 2026/10/30
JO - Pharmacoepidemiology and drug safety
DO - 10.1002/pds.70503
UR - https://europepmc.org/article/MED/42963129
AB - Aim To describe Australian trends in JAKi uptake, where there are no restrictions on the sequence of their use in clinical practice.Methods We included all people aged 18 years and over initiating a JAKi between 1 October 2015 and 31 August 2022. We used national dispensing claims data for a random 10% sample of Australians to: describe the number of people initiating JAKi per quarter; the characteristics of new JAKi users including demographics, use of other medicines to manage cardiovascular comorbid disease; and use of prior targeted therapy (biologics or small molecule inhibitors). We used Kaplan-Meier analysis to estimate the proportion of initiators who were persistent on their initial JAKi to 365 days.Results We identified 2904 people initiating JAKi treatment between 1 October 2015 and 31 August 2022; new use increased consistently during the study period. 45% of initiators had not been dispensed a prior subsidised targeted therapy in 365 days prior to JAKi initiation; 72% of new users were female and 62% were aged 55 years or older. Almost half of people initiating JAKi had at least one marker of higher cardiovascular risk, with 30% dispensed medicines to treat or prevent cardiovascular disease in the year prior to initiation; and 34% being aged 65 years or older. 60% of people persisted on their initial JAKi therapy to 365 days. Of those who stopped, 51% switched to a biologic and 15% switched to a different JAKi.Conclusion In a setting where JAKi are permitted to be used in any line of therapy, 45% of new users of JAKi were naïve to targeted therapy and half had at least one marker of cardiovascular risk. Continued monitoring is required to understand the risk profile of JAKi, particularly in those with high baseline cardiovascular disease risk.
SN - 1053-8569
SN - 1099-1557
ER -